Study design of ASPirin in Reducing Events in the Elderly (ASPREE): A randomized, controlled trial

R Grimm; JJ McNeil; W Applegate; L Beilin; S Espinoza; CI Johnston; B Kirpach; K Margolis; A Murray; MR Nelson; CM Reid; R Shah; E Storey; AM Tonkin; P Wilson; R Wolfe; RL Woods; W Abhayaratna; D Ames; L Cobiac; G Donnan; P Gibbs; R Head; H Krum; M Jelnik; M Malik; J Williamson; C Eaton; J Weissfeld; F MacRae; LM Rodriguez; R Shah; AB Newman; J Demons; B Workman; E Wood; S Satterfield; M Ernst; D Gilbertson; JE Lockery; J Hannah; B Radziszewska; A Thomas; G Gill; C Jackson; M Kidd; G Russell; G Pressman; V Figueredo; M Oberoi; M Ahmad; S Krstevska; C Lawson; S Katzman; J Powell; M Lang; P Bolin; VA Atlanta; A Le; T Johnson; D Kruger; T Obisesan; J Allard; K Dodd; B Ott; P Pemu; E Hadley; SV Romashkan; L Palaniappan; P Jose; T Church; V Myers; R Monce; N Britt; A Gupta; J Keller; B Lewis; J Shikany; R Allman; S Anton; M Pahor; J Burns; R Swerdlow; H Anderson; J Wiggins; L Nyquist; KA Peterson; H Tindle; KC Johnson; C Womack; L Birnbaum; S Nesbitt; E Volpi

Journal article

Study design of ASPirin in Reducing Events in the Elderly (ASPREE): A randomized, controlled trial

R Grimm, JJ McNeil, W Applegate, L Beilin, S Espinoza, CI Johnston, B Kirpach, K Margolis, A Murray, MR Nelson, CM Reid, R Shah, E Storey, AM Tonkin, P Wilson, R Wolfe, RL Woods, W Abhayaratna, D Ames, L Cobiac Show all

Contemporary Clinical Trials | ELSEVIER SCIENCE INC | Published : 2013

DOI: 10.1016/j.cct.2013.09.014

Abstract

Cost-effective strategies to maintain healthy active lifestyle in aging populations are required to address the global burden of age-related diseases. ASPREE will examine whether the potential primary prevention benefits of low dose aspirin outweigh the risks in older healthy individuals. Our primary hypothesis is that daily oral 100. mg enteric-coated aspirin will extend a composite primary endpoint termed 'disability-free life' including onset of dementia, total mortality, or persistent disability in at least one of the Katz Activities of Daily Living in 19,000 healthy participants aged 65. years and above ('US minorities') and 70. years and above (non-'US minorities'). ASPREE is a double-..

View full abstract

University of Melbourne Researchers

Colin Johnston Author

David Ames Author

Geoffrey Donnan Author

Peter Gibbs Author

Grants

Awarded by National Institute on Aging

Funding Acknowledgements

ASPREE is registered on the International Standard Randomized Controlled Trial Number Register (ISRCTN83772183). ASPREE has received project grants from the National Institute on Aging, the National Health and Medical Research Council (Australia), Heart Foundation (Australia), the National Cancer Institute and the Victorian Cancer Agency (Australia). Bayer Pharma AG provides blinded aspirin and placebo. ASPREE has multiple IRB approvals in the US and Australia.